A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
RESULTS Patient Eligibility: • Diagnosis was based on p16 positivity on immunohistochemistry and/or HPV positivity on in situ hybridization. • Patients were mostly treated with concurrent chemoradiation. • Those with PET/CT scans before and after treatment were investigated for RPLN positivity in the official radiology report of their imaging. PET/CT imaging: • RPLN positivity was defined as a lesion measuring 10 mm or larger in the shortest diameter on PET/CT and interpreted as adoi:10.1002/lary.25495 pmid:26227748 fatcat:iqwmb3a64ff75d6ojoptc3y3dm